Laryngeal carcinoma /hypopharyngeal carcinoma
Conditions
Interventions
experimental group:TP and Toripalimab neoadjuvant chemotherapy followed by Toripalimab concurrent radiotherapy
Sponsors
Sun Yat-Sen University Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with squamous cell carcinoma confirmed by histology and / or cytology; 2. The radiotherapy site must have at least one measurable focus patient who has passed MRI examination (RECIST 1.1 standard); 3. Clinical stage: t3-4n0-3m0 stage of laryngeal cancer, t2-3n0-3m0 stage of hypopharyngeal cancer (AJCC 8th Edition); 4. According to the criteria of the eastern tumor cooperation group (ECoG) (physical fitness score is 0 or 1); 5. The patient must be informed of the basic content of the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with previous history of severe hypersensitivity to any component of other monoclonal antibodies or PD-1 monoclonal antibodies; 2. Patients with other malignant tumors; 3. Patients with known or suspected autoimmune diseases and severe mental diseases; 4. Patients who have received systemic or local glucocorticoid treatment, need long-term use of immunosuppressive drugs or use of traditional anti-tumor herbs within 4 weeks before admission; 5. Patients who have been vaccinated with any anti infective vaccine (such as influenza vaccine, varicella vaccine, etc.) within 4 weeks before enrollment; 6. Pregnant and lactating women; 7. Patients younger than 18 or older than 65 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Local replase-free survival rate;larynx preserve rate;Quality of life;overall survival; | — |
Countries
China
Contacts
Public ContactAnkui Yang
Department of Head and Neck Surgery, Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center
Outcome results
None listed